Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 26, 2009

FIT Biotech and ImmunoVaccine Ally to Enhance HIV Vaccine Candidate

FIT Biotech and ImmunoVaccine Ally to Enhance HIV Vaccine Candidate

Preclinical technology partnership researches HIV vaccine

  • FIT Biotech and ImmunoVaccine Technologies (IVT) entered a preclinical research partnership to combine FIT's anti-HIV DNA plasmid with IVT's vaccine delivery system, DepoVax. GTU MiltiHIV is a synthetic DNA plasmid that covers the antigenic variability within HIV strains, attempting to counteract HIV's known ability to mutate rapidly and therefore avoid effective vaccine therapy.

    "DepoVax will act as a vector to deliver FIT Biotech's GTU MultiHIV DNA vaccine, and our goal is to develop a more sophisticated and efficient HIV vaccine candidate," says Marc Mansour, Ph.D., vp of R&D at IVT. DepoVax is a vaccine delivery system that delivers DNA plasmids into lymph nodes using liposomes to encapsulate a target antigen.


    Related News from IVT

    La Jolla Institute to Test IVT’s Delivery Platform with Infectious Disease Candidates (Mar. 27, 2009)
    ImmunoVaccine Technologies Receives Funding to Further Cancer and Infectious Disease Vaccine Development (Jan. 21, 2008)
    ImmunoVaccine Technologies to Take Over Immunotope (Dec. 10, 2007)

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »